about
Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroidLong-acting beta2-agonists for stable chronic asthmaComparison of spray congealing and melt emulsification methods for the incorporation of the water-soluble salbutamol sulphate in lipid microparticles.Preparation and in vitro evaluation of salbutamol-loaded lipid microparticles for sustained release pulmonary therapy.Human airway contraction and formoterol-induced relaxation is determined by Ca2+ oscillations and Ca2+ sensitivity.Asthma, airway biology, and nasal disorders in AJRCCM 2001.Beta-agonist intrinsic efficacy: measurement and clinical significance.Inhaled corticosteroids for asthma: common clinical quandaries.Nebulised salbutamol administered during sputum induction improves bronchoprotection in patients with asthma.Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover studyOvercoming gaps in the management of asthma in older patients: new insights.Inhaling medicines: delivering drugs to the body through the lungs.Differential desensitization of homozygous haplotypes of the beta2-adrenergic receptor in lymphocytesPharmacotherapy of asthma: regular treatment or on demand?Modulite technology in the development of formoterol HFA pMDI: clinical evidence and future opportunities.In vitro sensitization of human bronchus by beta2-adrenergic agonists.Effect of combining salmeterol and fluticasone on the progression of airway remodeling.Pranlukast, a cysteinyl leukotriene receptor 1 antagonist, attenuates allergen-specific tumour necrosis factor alpha production and nuclear factor kappa B nuclear translocation in peripheral blood monocytes from atopic asthmatics.A respiratory therapist-directed protocol for managing inpatients with asthma and COPD incorporating a long-acting bronchodilator.Pulmonary pharmacokinetics of tulathromycin in swine. Part 2: Intra-airways compartments.beta2-Adrenoceptor agonist modulates endothelin-1 receptors in human isolated bronchi.Double-blind, randomised, controlled trial assessing controller medications in asthma.Beta2-agonists use during pregnancy and the risk of congenital malformations.Writing a Review Article forAJRCCMUse and safety of long-acting β2-agonists for pediatric asthmaPolymorphism of Beta2-Adrenoceptor and Regular Use of Formoterol in Asthma: Preliminary Results
P2860
Q24246441-5E8AC12F-5CA9-43A1-9EC3-E65FDA8DEFC2Q24247926-6E88D404-21F8-46EB-8CAA-85F97311E6A6Q31097714-48A16524-282F-4E98-BDEA-CA4F7BFD41B4Q34114591-43BB1751-4665-4718-871F-912FDFB1F83AQ34118447-B1A996C0-1030-4AEE-93CF-BE1040E0245EQ34550135-3AF0ECB5-9397-471D-80C5-95175E758169Q34642515-773795D8-0A11-4A4F-882C-D57F6C434D01Q35135288-27766C27-B470-4271-8E68-7B4C0C281F2AQ35536463-603E8E0E-EC7B-43DB-BE86-290CE1BFAB4EQ35826407-1F3166EF-03BB-472E-88B3-D1EFF97BCC86Q36346376-E1D29D29-6290-4105-9906-2D04E17EC15DQ36694800-3345726A-302A-4937-907F-8D49980663C3Q37282807-C0760EC7-61F8-446E-8E40-E2D3772FF4DDQ37578103-B01482FC-431C-4F1F-BDAF-FD1C0B3EFF7EQ40129417-9C509A33-880D-4668-9A79-2DE40F57EF6CQ44176962-625DBE76-6B9D-414D-964B-DB17E4C60847Q44179176-8CBF1B40-ACAE-48B6-97E6-C383F0FF2EFFQ44474633-ABC92B2A-E3CA-4223-AC99-B2CBDAB625D1Q46413552-F70E9253-138C-48C1-BBA5-C9B7F94DD399Q46490969-C9700134-F49E-4EDF-B1C7-7E64116DBE6FQ46844432-738D5521-3FFE-41B8-AB26-33C7574C7F14Q46890689-3DEAAE51-1E42-497B-8047-0E968BBB6E25Q51528977-1702D64D-FC09-4F12-9246-C84346580813Q56457060-A0992838-6307-4D9A-AFBB-EE82637B95B4Q57821604-D7F000A2-C08B-4A21-AE4F-C803FD3DF4BFQ58993741-68CBADC5-EC4C-41E1-AC2A-5A1A3133E183
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Long-acting inhaled beta
@nl
Long-acting inhaled beta(2)-agonist therapy in asthma.
@ast
Long-acting inhaled beta(2)-agonist therapy in asthma.
@en
type
label
Long-acting inhaled beta
@nl
Long-acting inhaled beta(2)-agonist therapy in asthma.
@ast
Long-acting inhaled beta(2)-agonist therapy in asthma.
@en
prefLabel
Long-acting inhaled beta
@nl
Long-acting inhaled beta(2)-agonist therapy in asthma.
@ast
Long-acting inhaled beta(2)-agonist therapy in asthma.
@en
P2860
P1476
Long-acting inhaled beta(2)-agonist therapy in asthma.
@en
P2093
P2860
P304
P356
10.1164/AJRCCM.164.6.2010107
P407
P577
2001-09-01T00:00:00Z